Benchmark Upgrades OncoCyte Corp (OCX) to Buy
Get Alerts OCX Hot Sheet
Price: $3.20 --0%
Rating Summary:
4 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
4 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
Benchmark analyst Bruce Jackson upgraded OncoCyte Corp (NYSE: OCX) from Speculative Buy to Buy with a price target of $6.00.
For an analyst ratings summary and ratings history on OncoCyte Corp click here. For more ratings news on OncoCyte Corp click here.
Shares of OncoCyte Corp closed at $2.60 yesterday.
You May Also Be Interested In
- Northland Upgrades Hyliion Holdings (HYLN) to Outperform 'on Improved Visibility to KARNO Commercialization'
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Johnson Rice Upgrades Core Laboratories (CLB) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share